Cargando…

Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span

Epilepsy represents a complex spectrum disorder, with patients sharing seizures as a common symptom and manifesting a broad array of additional clinical phenotypes. To understand this disorder and treat individuals who live with epilepsy, it is important not only to identify pathogenic mechanisms un...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Jana E., Asato, Miya R., Brown, Mesha-Gay, Doss, Julia L., Felton, Elizabeth A., Kearney, Jennifer A., Talos, Delia, Dacks, Penny A., Whittemore, Vicky, Poduri, Annapurna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031803/
https://www.ncbi.nlm.nih.gov/pubmed/31973592
http://dx.doi.org/10.1177/1535759719895277
_version_ 1783499448644534272
author Jones, Jana E.
Asato, Miya R.
Brown, Mesha-Gay
Doss, Julia L.
Felton, Elizabeth A.
Kearney, Jennifer A.
Talos, Delia
Dacks, Penny A.
Whittemore, Vicky
Poduri, Annapurna
author_facet Jones, Jana E.
Asato, Miya R.
Brown, Mesha-Gay
Doss, Julia L.
Felton, Elizabeth A.
Kearney, Jennifer A.
Talos, Delia
Dacks, Penny A.
Whittemore, Vicky
Poduri, Annapurna
author_sort Jones, Jana E.
collection PubMed
description Epilepsy represents a complex spectrum disorder, with patients sharing seizures as a common symptom and manifesting a broad array of additional clinical phenotypes. To understand this disorder and treat individuals who live with epilepsy, it is important not only to identify pathogenic mechanisms underlying epilepsy but also to understand their relationships with other health-related factors. Benchmarks Area IV focuses on the impact of seizures and their treatment on quality of life, development, cognitive function, and other aspects and comorbidities that often affect individuals with epilepsy. Included in this review is a discussion on sudden unexpected death in epilepsy and other causes of mortality, a major area of research focus with still many unanswered questions. We also draw attention to special populations, such as individuals with nonepileptic seizures and pregnant women and their offspring. In this study, we review the progress made in these areas since the 2016 review of the Benchmarks Area IV and discuss challenges and opportunities for future study.
format Online
Article
Text
id pubmed-7031803
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70318032020-03-03 Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span Jones, Jana E. Asato, Miya R. Brown, Mesha-Gay Doss, Julia L. Felton, Elizabeth A. Kearney, Jennifer A. Talos, Delia Dacks, Penny A. Whittemore, Vicky Poduri, Annapurna Epilepsy Curr Reviews Epilepsy represents a complex spectrum disorder, with patients sharing seizures as a common symptom and manifesting a broad array of additional clinical phenotypes. To understand this disorder and treat individuals who live with epilepsy, it is important not only to identify pathogenic mechanisms underlying epilepsy but also to understand their relationships with other health-related factors. Benchmarks Area IV focuses on the impact of seizures and their treatment on quality of life, development, cognitive function, and other aspects and comorbidities that often affect individuals with epilepsy. Included in this review is a discussion on sudden unexpected death in epilepsy and other causes of mortality, a major area of research focus with still many unanswered questions. We also draw attention to special populations, such as individuals with nonepileptic seizures and pregnant women and their offspring. In this study, we review the progress made in these areas since the 2016 review of the Benchmarks Area IV and discuss challenges and opportunities for future study. SAGE Publications 2020-01-23 /pmc/articles/PMC7031803/ /pubmed/31973592 http://dx.doi.org/10.1177/1535759719895277 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc-nd/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Reviews
Jones, Jana E.
Asato, Miya R.
Brown, Mesha-Gay
Doss, Julia L.
Felton, Elizabeth A.
Kearney, Jennifer A.
Talos, Delia
Dacks, Penny A.
Whittemore, Vicky
Poduri, Annapurna
Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
title Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
title_full Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
title_fullStr Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
title_full_unstemmed Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
title_short Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across the Life Span
title_sort epilepsy benchmarks area iv: limit or prevent adverse consequence of seizures and their treatment across the life span
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031803/
https://www.ncbi.nlm.nih.gov/pubmed/31973592
http://dx.doi.org/10.1177/1535759719895277
work_keys_str_mv AT jonesjanae epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT asatomiyar epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT brownmeshagay epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT dossjulial epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT feltonelizabetha epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT kearneyjennifera epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT talosdelia epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT dackspennya epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT whittemorevicky epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT poduriannapurna epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan
AT epilepsybenchmarksareaivlimitorpreventadverseconsequenceofseizuresandtheirtreatmentacrossthelifespan